Literature DB >> 10380356

Inhibition of cysteine proteases by peptides containing aziridine-2,3-dicarboxylic acid building blocks.

T Schirmeister1.   

Abstract

Mammalian cysteine proteases of the papain superfamily are interesting targets for the development of new drugs against diseases connected to abnormal degradation of muscle or bone proteins. The high nucleophilicity of the active site of these proteases as well as the characteristics of the well-known epoxysuccinic acid derived cysteine protease inhibitors provided a basis for the design of new types of selective and irreversible inhibitors for these enzymes. We designed and synthesized a novel class of peptidic cysteine protease inhibitors containing aziridine-2,3-dicarboxylic acid as electrophilic amino acid. Three types of aziridinyl peptides that differ in the position of the aziridine building block within the peptide chain have been synthesized and tested as inhibitors of several cysteine proteases. Remarkable differences could be observed between the three types of inhibitors concerning their activity, stereospecificity, pH dependency of inhibition, and selectivity between different cysteine proteases, respectively, indicating that different binding modes of the three types of inhibitors in respect to their orientation in the S and S' binding sites of the enzymes may be present.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10380356     DOI: 10.1002/(SICI)1097-0282(1999)51:1<87::AID-BIP10>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  3 in total

1.  Aziridine-2,3-dicarboxylate-based cysteine cathepsin inhibitors induce cell death in Leishmania major associated with accumulation of debris in autophagy-related lysosome-like vacuoles.

Authors:  Uta Schurigt; Caroline Schad; Christin Glowa; Ulrike Baum; Katja Thomale; Johannes K Schnitzer; Martina Schultheis; Norbert Schaschke; Tanja Schirmeister; Heidrun Moll
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

2.  Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases.

Authors:  Caroline Schad; Ulrike Baum; Benjamin Frank; Uwe Dietzel; Felix Mattern; Carlos Gomes; Alicia Ponte-Sucre; Heidrun Moll; Uta Schurigt; Tanja Schirmeister
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

3.  (Z)-N-[1-(Aziridin-1-yl)-2,2,2-tri-fluoro-ethyl-idene]-4-bromo-aniline.

Authors:  Alexander S Bunev; Maksim A Vasiliev; Gennady I Ostapenko; Alexander S Peregudov; Victor N Khrustalev
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-04-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.